Tag: Anchiano Therapeutics

Anchiano Discontinues Phase 2 Codex Study

The company discontinued its Phase 2 Codex study evaluating the gene therapy inodiftagene vixteplasmid in bladder cancer.

Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering

Anchiano Therapeutics (NASDAQ:ANCN) has announced it has priced its initial public offering of 2.65 million shares at a price of...

Which Life Science IPOs is the Government Shutdown Affecting?

Initial public offerings meant to take place are facing a huge barrier due to the ongoing US government shutdown.